Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

ErbB1 / HER-1 / EGFR tyrosine kinase inhibitors + Pyrimidines & Pancreatic ductal adenocarcinoma (PDAC) / Pancreatic cancer

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Erlotinib and gemcitabine, as an example for ErbB1 / HER-1 / EGFR tyrosine kinase inhibitors + Pyrimidines, work well together for pancreatic cancer. This combination showed a small but significant survival benefit. It was proven in a phase III trial for advanced pancreatic cancer. Other similar drug combinations have not been as successful. Most remain in early testing or have not shown positive results.
Walsh et al. 2013 Invest New Drugs 31(3): 558-66

EGFR and HER2 inhibition in pancreatic cancer
Walsh et al. 2013 Invest New Drugs 31(3): 558-66

7/1/2026